Agios Pharmaceuticals, Inc. (AGIO) shareholders
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Farallon Capital Management, L.L.C. Joint filing with Dapice Joshua J. (9.90%), Dreyfuss, Philip D. (9.90%) and 13 more | 5,917,400 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Short Daniel S. Joint filing with Wehrly, Mark C. (9.90%), Seybold, William (9.90%) and 17 more | 5,674,466 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Gehani, Varun N. Joint filing with Wehrly, Mark C. (8.80%), Short Daniel S. (8.80%) and 15 more | 5,159,505 | 8.80% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 4,513,170 | 7.80% | 13G (passive) amendment | Jun 30, 2025 |
| State Street Corporation | 3,108,145 | 5.30% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 3,088,169 | 5.27% | 13G (passive) | Mar 31, 2026 |
| D. E. Shaw & Co., L.P. Joint filing with David E. Shaw (5.10%) | 3,034,031 | 5.10% | 13G (passive) | Jun 25, 2026 |
| Senai Asefaw, M.D. Joint filing with Paradigm BioCapital Advisors LP (5.20%), Paradigm BioCapital Advisors GP LLC (5.20%) | 3,027,977 | 5.20% | 13G (passive) | Aug 21, 2025 |
| Weston Nichols Joint filing with Lynx1 Capital Management LP (5.10%) | 3,013,949 | 5.10% | 13G (passive) | Apr 29, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AGIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,455,997 | 10.81% | $239.58M | +701,040 | 0.00% |
| Farallon Capital Management LLC | 5,917,400 | 9.91% | $219.59M | +233,400 | 1.01% |
| State Street Corp | 3,533,633 | 5.92% | $131.14M | +168,754 | 0.00% |
| Lynx1 Capital Management LP | 3,408,937 | 5.71% | $126.51M | +797,369 | 14.62% |
| D. E. Shaw & Co., Inc. | 3,107,005 | 5.20% | $115.30M | +425,836 | 0.05% |
| Vanguard Portfolio Management LLC | 2,898,197 | 4.85% | $107.55M | +287,162 | 0.00% |
| Vanguard Capital Management LLC | 2,681,845 | 4.49% | $99.52M | +49,529 | 0.00% |
| Armistice Capital, LLC | 2,400,000 | 4.02% | $89.06M | −316,000 | 1.09% |
| Erste Asset Management GmbH | 2,154,900 | 3.61% | $81.97M | −550,000 | 0.64% |
| Nomura Asset Management International Inc. | 2,110,809 | 3.54% | $78.33M | +616,374 | 0.12% |
| Geode Capital Management, LLC | 1,574,268 | 2.64% | $58.43M | +106,358 | 0.00% |
| Susquehanna International Group, Llp | 1,375,558 | 2.30% | $51.05M | +30,605 | 0.00% |
| ADAR1 Capital Management, LLC | 1,288,053 | 2.16% | $47.80M | +1,147,381 | 2.19% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,280,044 | 2.14% | $47.50M | −300,796 | 0.05% |
| Dimensional Fund Advisors LP | 1,248,738 | 2.09% | $46.35M | +97,124 | 0.01% |
| GW&K Investment Management, LLC | 1,206,615 | 2.02% | $44.78M | −8,286 | 0.35% |
| Goldman Sachs Group Inc | 1,150,932 | 1.93% | $42.71M | +345,156 | 0.00% |
| UBS Group AG | 985,831 | 1.65% | $36.58M | +853,291 | 0.00% |
| Morgan Stanley | 963,256 | 1.61% | $35.75M | −4,269 | 0.00% |
| Nuveen, LLC | 873,560 | 1.46% | $32.42M | +151,212 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 238 | 66M | 100.0% | 39 / 97 | 65 / 32 | 13M | 10M |
| Q1 2026 | 234 | 63M | 100.0% | 36 / 82 | 82 / 37 | 16M | 9M |
| Q4 2025 | 238 | 61M | 100.0% | 65 / 78 | 71 / 44 | 20M | 22M |
| Q3 2025 | 221 | 64M | 100.0% | 43 / 68 | 69 / 35 | 9M | 7M |
| Q2 2025 | 215 | 62M | 100.0% | 21 / 87 | 77 / 25 | 7M | 5M |
| Q1 2025 | 221 | 60M | 100.0% | 38 / 73 | 78 / 39 | 8M | 7M |
| Q4 2024 | 225 | 60M | 100.0% | 41 / 85 | 71 / 24 | 8M | 8M |
| Q3 2024 | 208 | 60M | 100.0% | 27 / 76 | 69 / 24 | 10M | 5M |
| Q2 2024 | 206 | 60M | 100.0% | 48 / 52 | 81 / 27 | 8M | 15M |
| Q1 2024 | 187 | 67M | 100.0% | 40 / 61 | 58 / 23 | 11M | 7M |
| Q4 2023 | 170 | 63M | 100.0% | 36 / 62 | 48 / 8 | 11M | 7M |
| Q3 2023 | 145 | 59M | 99.2% | 10 / 56 | 46 / 17 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
224 funds held AGIO in Q2 2026, 61% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AGIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,005,301 | 3.36% | $74.42M | 0.69% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,889,447 | 3.16% | $70.12M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,539,675 | 2.58% | $57.14M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,362,732 | 2.28% | $50.57M | 0.03% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 1,144,753 | 1.92% | $33.66M | 0.61% | May 29, 2026 |
| Vanguard Small-Cap Growth Index Fund | 788,655 | 1.32% | $29.27M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 683,990 | 1.15% | $25.38M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 646,318 | 1.08% | $19.40M | 0.06% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 520,310 | 0.87% | $19.31M | 0.13% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 481,926 | 0.81% | $14.17M | 0.01% | May 31, 2026 |
| iShares Biotechnology ETF | 395,471 | 0.66% | $14.68M | 0.16% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 332,643 | 0.56% | $12.34M | 0.01% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 308,070 | 0.52% | $9.25M | 0.23% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 303,759 | 0.51% | $8.93M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 290,173 | 0.49% | $8.53M | 0.05% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brian Goff | Chief Executive Officer, Director | 191,104 | 0.32% | Jun 23, 2026 |
| Sarah Gheuens | Chief Medical Officer | 54,645 | 0.09% | Oct 28, 2026 |
| Tsveta Milanova | Chief Commercial Officer | 46,829 | 0.08% | Jun 23, 2026 |
| Krishnan Viswanadhan | Chief Strategy and Operations | 10,282 | 0.02% | Jun 23, 2026 |
| James William Burns | Chief Legal Officer | 49,306 | 0.08% | Jun 23, 2026 |
| Cecilia Jones | Chief Financial Officer | 54,998 | 0.09% | Jun 23, 2026 |
| Theodore James Washburn Jr. | Principal Accounting Officer | 868 | 0.00% | Mar 5, 2026 |
| Jay T. Backstrom | Director | 1,447 | 0.00% | Jul 10, 2026 |
| Rahul D. Ballal | Director | 15,230 | 0.03% | Jun 23, 2026 |
| Cynthia Smith | Director | 15,230 | 0.03% | Jun 23, 2026 |
| David Scadden | Director | 20,419 | 0.03% | Jun 23, 2026 |
| Maykin Ho | Director | 19,848 | 0.03% | Jun 23, 2026 |
| Jacqualyn A. Fouse | Director | 154,156 | 0.26% | Jun 23, 2026 |
| Jeffrey D. Capello | Director | 10,865 | 0.02% | Jun 23, 2026 |
| Adams Catherine Owen | Director | 10,865 | 0.02% | Jun 23, 2026 |
| Kaye I. Foster-Cheek | Director | 12,484 | 0.02% | Jun 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sarah Gheuens Chief Medical Officer | Oct 26, 2026 | Sale(10b5-1 plan) | −7,866 | $37.69 | $296.47K | 54,645 |
| Sarah Gheuens Chief Medical Officer | Oct 26, 2026 | Option exercise | +7,866 | $25.01 | $196.73K | 62,511 |
| Sarah Gheuens Chief Medical Officer | Oct 22, 2026 | Sale(10b5-1 plan) | −500 | $37.52 | $18.76K | 54,645 |
| Sarah Gheuens Chief Medical Officer | Oct 22, 2026 | Option exercise | +500 | $25.01 | $12.51K | 55,145 |
| Sarah Gheuens Chief Medical Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −1,489 | $37.53 | $55.88K | 54,645 |
| Sarah Gheuens Chief Medical Officer | Oct 21, 2026 | Option exercise | +1,489 | $25.01 | $37.24K | 56,134 |
| Sarah Gheuens Chief Medical Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −30,000 | $30.48 | $914.40K | 54,645 |
| Jay T. Backstrom Director | Jul 8, 2026 | Award | +1,447 | – | – | 1,447 |
| Sarah Gheuens Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −4,007 | $37.56 | $150.50K | 84,645 |
| Sarah Gheuens Chief Medical Officer | Jul 1, 2026 | Option exercise | +8,375 | – | – | 88,652 |
| Cynthia Smith Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 15,230 |
| Jeffrey D. Capello Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 10,865 |
| Maykin Ho Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 19,848 |
| Kaye I. Foster-Cheek Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 10,284 |
| Adams Catherine Owen Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 10,865 |
| Jacqualyn A. Fouse Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 154,156 |
| David Scadden Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 20,419 |
| Rahul D. Ballal Director | Jun 18, 2026 | Option exercise | +2,816 | – | – | 15,230 |
| Adams Catherine Owen Director | Jun 13, 2026 | Option exercise | +1,976 | – | – | 8,049 |
| Jeffrey D. Capello Director | Jun 13, 2026 | Option exercise | +1,976 | – | – | 8,049 |
| Tsveta Milanova Chief Commercial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −3,262 | $34.71 | $113.22K | 46,829 |
| Tsveta Milanova Chief Commercial Officer | Apr 2, 2026 | Option exercise | +8,500 | – | – | 50,091 |
| Cecilia Jones Chief Financial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −3,141 | $34.71 | $109.02K | 54,998 |
| Cecilia Jones Chief Financial Officer | Apr 2, 2026 | Option exercise | +8,500 | – | – | 58,139 |
| James William Burns Chief Legal Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −3,280 | $34.71 | $113.85K | 49,306 |
| James William Burns Chief Legal Officer | Apr 2, 2026 | Option exercise | +8,500 | – | – | 52,586 |
| Krishnan Viswanadhan Chief Corp Dev & Strategy | Apr 2, 2026 | Sale(10b5-1 plan) | −2,959 | $34.71 | $102.71K | 10,282 |
| Krishnan Viswanadhan Chief Corp Dev & Strategy | Apr 2, 2026 | Option exercise | +8,100 | – | – | 13,241 |
| Brian Goff Chief Executive Officer, Director | Apr 2, 2026 | Option exercise | +13,500 | – | – | 191,104 |
| Brian Goff Chief Executive Officer, Director | Apr 2, 2026 | Option exercise | +25,528 | – | – | 190,076 |
| Brian Goff Chief Executive Officer, Director | Apr 2, 2026 | Sale(10b5-1 plan) | −6,596 | $34.71 | $228.95K | 184,508 |
| Brian Goff Chief Executive Officer, Director | Apr 2, 2026 | Sale(10b5-1 plan) | −12,472 | $34.71 | $432.90K | 177,604 |
| Sarah Gheuens Chief Medical Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −2,940 | $34.71 | $102.05K | 80,277 |
| Sarah Gheuens Chief Medical Officer | Apr 2, 2026 | Option exercise | +8,500 | – | – | 83,217 |
| Krishnan Viswanadhan Chief Corp Dev & Strategy | Mar 5, 2026 | Option exercise | +8,100 | – | – | 8,100 |
| Krishnan Viswanadhan Chief Corp Dev & Strategy | Mar 5, 2026 | Sale(10b5-1 plan) | −2,959 | $27.80 | $82.26K | 5,141 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 3, 2026 | Sale | −5,272 | $28.88 | $152.26K | 868 |
| Brian Goff Chief Executive Officer, Director | Mar 2, 2026 | Option exercise | +13,000 | – | – | 170,466 |
| Brian Goff Chief Executive Officer, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −8,267 | $28.96 | $239.41K | 157,466 |
| Brian Goff Chief Executive Officer, Director | Mar 2, 2026 | Option exercise | +18,000 | – | – | 165,733 |
| Brian Goff Chief Executive Officer, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −3,870 | $28.96 | $112.08K | 147,733 |
| Brian Goff Chief Executive Officer, Director | Mar 2, 2026 | Option exercise | +8,500 | – | – | 151,603 |
| Brian Goff Chief Executive Officer, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −5,918 | $28.96 | $171.39K | 164,548 |
| Tsveta Milanova Chief Commercial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,681 | $28.96 | $48.68K | 38,778 |
| Tsveta Milanova Chief Commercial Officer | Mar 2, 2026 | Option exercise | +5,666 | – | – | 40,459 |
| Tsveta Milanova Chief Commercial Officer | Mar 2, 2026 | Option exercise | +4,000 | – | – | 42,778 |
| Tsveta Milanova Chief Commercial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,187 | $28.96 | $34.38K | 41,591 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 2, 2026 | Option exercise | +2,350 | – | – | 3,293 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 2, 2026 | Option exercise | +2,450 | – | – | 4,970 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −798 | $28.96 | $23.11K | 6,140 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 2, 2026 | Option exercise | +2,695 | – | – | 6,938 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −727 | $28.96 | $21.05K | 4,243 |
| Theodore James Washburn Jr. Principal Accounting Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −698 | $28.96 | $20.21K | 2,595 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,163 | $28.96 | $33.68K | 44,086 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Option exercise | +3,920 | – | – | 45,249 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,187 | $28.96 | $34.38K | 41,329 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Option exercise | +4,000 | – | – | 42,516 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,681 | $28.96 | $48.68K | 38,516 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Option exercise | +5,666 | – | – | 40,197 |
| James William Burns Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,187 | $28.96 | $34.38K | 34,531 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Agios Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sarah Gheuens Officer | Oct 26, 2026 | 7,866 | $296.47K | Oct 26, 2026 | Stock Option Exercise |
| Sarah Gheuens Officer | Oct 22, 2026 | 500 | $18.76K | Oct 22, 2026 | Stock Option Exercise |
| Sarah Gheuens Officer | Oct 21, 2026 | 1,489 | $55.88K | Oct 21, 2026 | Stock Option Exercise |
| Sarah Gheuens Officer | Aug 4, 2026 | 30,000 | $914.28K | Aug 4, 2026 | Restricted Stock |
| Sarah Gheuens Officer | Jul 1, 2026 | 4,007 | $150.50K | Jul 1, 2026 | Vesting of restricted stock units |
| James William Burns Officer | Apr 2, 2026 | 3,280 | $112.14K | Apr 2, 2026 | Vesting of Restricted Stock Units |
| Sarah Gheuens Officer | Apr 2, 2026 | 2,940 | $100.52K | Apr 2, 2026 | Vesting of Restricted Stock Units |
| Tsveta Milanova Officer | Apr 2, 2026 | 3,262 | $111.53K | Apr 2, 2026 | Vesting of Restricted Stock Units |
| Krishnan Viswanadhan Officer | Apr 2, 2026 | 2,959 | $101.17K | Apr 2, 2026 | Vesting of Restricted Stock Units |
| Cecilia Jones Officer | Apr 2, 2026 | 3,141 | $107.39K | Apr 2, 2026 | Vesting of Restricted Stock Units |
| Brian Goff Officer, Director | Apr 2, 2026 | 19,068 | $651.94K | Apr 2, 2026 | Vesting of Restricted Stock Units |
| Krishnan Viswanadhan Officer | Mar 5, 2026 | 2,959 | $85.81K | Mar 5, 2026 | Vesting of Restricted Stock Units |
| Tsveta Milanova Officer | Mar 2, 2026 | 2,868 | $86.70K | Mar 2, 2026 | Vesting of Restricted Stock Units |
| Cecilia Jones Officer | Mar 2, 2026 | 5,035 | $152.21K | Mar 2, 2026 | Vesting of Restricted Stock Units |
| Sarah Gheuens Officer | Mar 2, 2026 | 4,055 | $122.58K | Mar 2, 2026 | Vesting of Restricted Stock Units |
Congress trades
8 trades in Agios Pharmaceuticals reported by 3 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Aug 20, 2026 | $1K–15K | Sep 10, 2026 |
| Gilbert Cisneros CA31 | Bought | Mar 3, 2026 | $1K–15K | Apr 7, 2026 |
| Gilbert Cisneros CA31 | Bought | Dec 11, 2025 | $1K–15K | Jan 12, 2026 |
| Gilbert Cisneros CA31 | Bought | Apr 17, 2025 | $1K–15K | May 6, 2025 |
| Gilbert Cisneros CA31 | Bought | Jan 29, 2025 | $1K–15K | Feb 11, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Jan 24, 2024 | $1K–15K | Feb 15, 2024 |
| Thomas MacArthur NJ03 · joint account | Sold | May 27, 2015 | $1K–15K | Jun 7, 2015 |
| Thomas MacArthur NJ03 · joint account | Bought | Mar 18, 2015 | $1K–15K | Apr 11, 2015 |
See a number that looks wrong?